Efficacy and Safety of Opinercept Tumor Necrosis Factor Inhibitor Therapy for Drug-Refractory Rheumatoid Arthritis: A Randomized Clinical Trial
1Department of Internal Medicine, Taipei City Hospital Renai Branch, Taipei, Taiwan
2Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
3Department of Internal Medicine, Cheng Hsin General Hospital, Taipei, Taiwan
4Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan
5Division of Rheumatology and Immunology, Cathay General Hospital, Taipei, Taiwan
6National Taiwan University, Graduate Institute of Immunology, College of Medicine, Taipei, Taiwan
7Department of Medicine, Cheng Hsin General Hospital, Taipei, Taiwan
Keywords: Clinical trial, disease-modifying anti-rheumatic drugs, opinercept, rheumatoid arthritis
Objectives: This study aims to evaluate the efficacy and safety profile of opinercept for rheumatoid arthritis (RA) patients undergoing disease- modifying anti-rheumatic drugs (DMARDs) therapy.
Patients and methods: A total of 98 patients with active RA (17 males, 81 females; mean age 58.6±12.2 years; range, 24.3 to 85.3 years) were randomized into opinercept plus DMARDs (OD group) or placebo plus DMARDs (PD group), in a 24-week treatment period. Primary outcome was American College of Rheumatology score (ACR20) at week 24. Other exploratory endpoints included ACR50, ACR70 and disease activity score-28 (DAS28) at week 12 and 24, tender/swollen joint counts, pain, Health Assessment Questionnaire-Disability Index, erythrocyte sedimentation rate, and C-reactive protein level. Incidence of adverse events (AEs), vital signs and physical findings, and laboratory test results were also evaluated.
Results: Patients in OD group showed significantly higher achievement percentage of ACR20 at week 24 than the PD group (76.6% vs. 30.3%, p<0.001). The evaluation of DAS28 was significantly improved in OD patients compared to PD patients at weeks 12 and 24. Most of the occurred AEs were mild or moderate and considered unrelated to study treatments.
Conclusion: Opinercept concurrent with DMARDs was superior to DMARDs alone in slowing RA progression and ameliorating symptoms, with well- tolerated and acceptable safety profile.
Citation: Liang TH, Lee CS, Lee SS, Wu CS, Chen KH, Hsu PN, et al. Efficacy and Safety of Opinercept Tumor Necrosis Factor Inhibitor Therapy for Drug-Refractory Rheumatoid Arthritis: A Randomized Clinical Trial. Arch Rheumatol 2020;35(2):170-179.
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
Toong-Hua Liang reported receiving personal fees from Mycenax Biotech. Chyou-Shen Lee reported receiving personal fees from Chugai, Tanabe and UCB. Shinn-Shing Lee reported receiving personal fees from AbbVie, Amgen, Astellas, Bristol-Myers Squobb, Chugai, Pfizer, Novartis, Roche and Johnson & Johnson. Chien- Sheng Wu reported receiving personal fees from AbbVie, Bristol-Myers Squibb, Chugai, Eisai, Johnson & Johnson, Tanabe, Novartis, Pfizer, Roche and Mycenax Biotech. Chien-Sheng Wu reported receiving grant support from AbbVie and Mycenax Biotech. Kun-Hung Chen reported receiving personal fees from AbbVie, Bristol-Myers Squobb, Chugai, Pfizer, Novartis, Tanabe, Mycenax Biotech and UCB. Ping-Ning Hsu reported receiving personal fees from AbbVie, Pfizer, Roche, Bristol-Myers Squibb, Novartis, Johnson & Johnson and Mycenax Biotech. Ping-Ning Hsu reported receiving grant support from AbbVie, Johnson & Johnson, Pfizer and Mycenax Biotech. Hsiao-Yi Lin reported receiving personal fees from Mycenax Biotech.
The authors thank Dr. David Neil (PhD), of Content Ed Net (Taiwan) for professional medical writing services, which were remunerated by Mycenax Biotech Corporation. Ltd., Taiwan.